| 2024 Ad Spend | What is it for? | Company | Answer | % Correct |
|---|---|---|---|---|
| $177.6 million | Diabetes | Novo Nordisk | Ozempic | 100%
|
| $484.1 million | Immunology | Sanofi and Regeneron | Dupixent | 0%
|
| $216.7 million | Diabetes and heart failure | Boehringer Ingelheim and Eli Lilly | Jardiance | 0%
|
| $171.6 million | Immunology | Amgen | Otezla | 0%
|
| $286.3 million | Antipsychotic | Lundbeck and Otsuka | Rexulti | 0%
|
| $552.6 million | Immunology | AbbVie | Rinvoq | 0%
|
| $647.1 million | Immunology | AbbVie | Skyrizi | 0%
|
| $247.6 million | Immunology | Johnson & Johnson | Tremfya | 0%
|
| $172.8 million | Antipsychotic | AbbVie | Vraylar | 0%
|
| $352.5 million | Obesity | Novo Nordisk | Wegovy | 0%
|